Nachrichten zur Pfizer Inc. Aktie

Non-Oncology Biologics and Biosimilars Market is Booming and Expected to Grow at a CAGR of 21.8% to 2031

Companies covered in this report are AbbVie Inc., Sanofi, Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La…

Eight Beaten-Down Stocks Including Pfizer and Hasbro That Look Like Bargains

…

Pfizer Inc. (PFE) 6th Annual Evercore ISI HealthCONx Conference (Transcript)

…

4 Large Drug Stocks to Watch as IBD Market Gains Traction

As demand for novel IBD treatments rises, investment in this dynamic sector could be rewarding. Some of the key players…

Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium

-- Six abstracts have been accepted for presentation, including updated data on vepdegestrant alone and in combination with palbociclib (IBRANCE®)…

Global Cold Pain Therapy Market Size Worth USD 2.92 Billion by 2032 | CAGR of 5.2%

The Global Cold Pain Therapy Market Size was valued at USD 1.76 Billion in 2022 and the Worldwide Cold Pain…

Global Printing Ink Market Size Worth USD 35.93 Billion by 2032 | CAGR of 6.7%

The Global Cold Pain Therapy Market Size was valued at USD 1.76 Billion in 2022 and the Worldwide Cold Pain…

How To Earn $500 A Month From Pfizer Stock

…

Mastercard, Pfizer Among 18 Companies To Announce Dividend Increases In December

…

dpa-AFX: JPMorgan belässt Pfizer auf Neutral - Ziel 34 Dollar

NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Pfizer-Aktie mit Blick auf die Kursschwäche in diesem Jahr auf "Neutral"…

JPMorgan belässt Pfizer auf Neutral - Ziel 34 Dollar

NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Pfizer-Aktie mit Blick auf die Kursschwäche in diesem Jahr auf…

Rising Global Prevalence of Skin Diseases Drives the Antipruritics Market, Future Market Insights Predicts Expansion at a 4.2% CAGR through 2034

The growing geriatric population, rising burden of skin diseases, and rising R&D on novel biopharmaceuticals. AbbVie Inc., Allergan, Merck &…

Pfizer: Abwärtspotenzial nach Ausverkauf ziemlich begrenzt - Aktienanalyse

New York (www.aktiencheck.de) - Pfizer-Aktienanalyse von J.P. Morgan Securities: Die Analysten von J.P. Morgan Securities bewerten die Aktie von Pfizer Inc.…

Synthetic Hormones Market Analysis Report 2023-2033, Featuring Profiles of Eli Lilly, Pfizer, Ferring, Merck, Novo Nordisk, Bayer, Novartis and More

Dublin, Nov. 27, 2023 (GLOBE NEWSWIRE) -- The "Global Synthetic Hormones Market: Focus on Product Type, Application, Route…

Global Glaucoma Treatment Market Size To Grow USD 10.5 Billion by 2032 | CAGR of 5.0%

The Global Glaucoma Treatment Market Size was valued at USD 6.4 Billion in 2022 and the Worldwide Glaucoma Treatment Market…

[Latest] Global Acne Treatment Market Size/Share Worth USD 18.77 Billion by 2032 at a 6.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global…

Oncology Drug Discovery & Development Market Expected to Grow at a CAGR of 18.2% from 2023 to 2031 | Reveals InsightAce Study

Companies covered in this study are Novartis, AstraZeneca, Merck & Co., Inc, Bristol-Myers Squibb, Pfizer, Eli Lilly and Company, Gilead…

Pfizers stock price is at a three-year low. Is it time to buy?

This heavily sold-off pharma stock is a bargain, so is it time to buy?…

Europäisches Patentamt erklärt Moderna-Patent für nichtig

Frankfurt (Reuters) - Das Europäische Patentamt hat im Patentstreit zwischen den beiden Corona-Impfstoffherstellern BioNTech und Moderna ein mRNA-Patent des US-Biotechkonzerns…

Pfizer Is A Fantastic Buy And So Are These 9%-Yielding Blue Chips

…

Impfstoffentwickler: EU-Patentamt hat Moderna-Patent für nichtig erklärt

Ende August hatte die US-Biotech-Firma Moderna das Mainzer Unternehmen Biontech und dessen US-Partner Pfizer verklagt. Das Urteil fiel nun zugunsten…

Texas AG sues Pfizer over quality-control lapses in kids ADHD drug By Reuters

Texas AG sues Pfizer over quality-control lapses in kids ADHD drug…

Texas AG sues Pfizer for alleged Medicaid fraud over ADHD meds

…

Pfizer Is Working on Oral Alternative to Ozempic

Pfizer CEO Albert Bourla says the drug maker is hoping to develop an oral anti-obesity drug that can rival Ozempic.…

Basilea Pharmaceutica AG: Weiterhin gute Cresemba® (Isavuconazol)-Umsätze in der Region Asien-Pazifik und China lösen dritte Meilensteinzahlung von Pfizer in diesem Jahr für diese Region aus

Allschwil, 20. November 2023 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel,…

GNW-Adhoc: Weiterhin gute Cresemba® (Isavuconazol)-Umsätze in der Region Asien-Pazifik und China lösen dritte Meilensteinzahlung von Pfizer in diesem Jahr für diese Region aus

^Allschwil, 20. November 2023 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel,…

GNW-Adhoc: Weiterhin gute Cresemba® (Isavuconazol)-Umsätze in der Region Asien-Pazifik und China lösen dritte Meilensteinzahlung von Pfizer in diesem Jahr fü...

^Allschwil, 20. November 2023Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutischesUnternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zuhelfen,…

Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers third sales milestone payment for the region from Pfizer this year

Allschwil, Switzerland, November 20, 2023…

GlobeNewswire: Weiterhin gute Cresemba® (Isavuconazol)-Umsätze in der Region Asien-Pazifik und China lösen dritte Meilensteinzahlung von Pfizer in diesem Jahr für diese Region aus

Weiterhin gute Cresemba® (Isavuconazol)-Umsätze in der Region Asien-Pazifik und China lösen dritte Meilensteinzahlung von Pfizer in diesem Jahr für diese…

Pfizer Stock: Cheap But Will Remain Cheap, For Now

…

Why the Cheapest Stock in the S&P 500 Is No Bargain

Viatris is the old generic drug company Mylan, acquired by Pfizer and merged with its Upjohn division. The stock has…

AbbVie and Pfizer Have 1 Thing in Common: Their Biggest Products Are on the Decline. Time to Sell? @themotleyfool #stocks $ABBV $PFE

Both companies share prices have slipped recently.…

AbbVie and Pfizer Have 1 Thing in Common: Their Biggest Products Are on the Decline. Time to Sell?

Both companies share prices have slipped recently.…

Pfizers (PFE) New Products May Drive Long-Term Sales Growth

Though Pfizers (PFE) revenues from COVID products are declining sharply, the launch of some key non-COVID products in 2023 is…

Eli Lillys Olumiant and Pfizers Litfulo Strengthen Alopecia Areata Arsenal, Yet Resounding Opportunity for JAK Expansion and New Assets in Development Remain

Despite little prescriber differentiation between the JAKs, including satisfaction and manufacturer perceptions, Olumiant is projected to maintain a significant market…

Pfizer to halve UK workforce at Discovery Park

Pfizer Inc (NYSE:PFE) has said it will lay off more than half of its employees at a UK-based scientific research centre…

Pfizer: Victim Of Vaccine Side Effects

…

Pfizer to shed 500 jobs at England site as cost-cutting ramps up

…

Pfizer to cut 500 jobs at Kent site

Pfizer is cutting 500 jobs at its Sandwich, Kent site in the U.K. as part of a cost-cutting effort, Sky…

Pfizer to cut 500 jobs at Kent site - Sky News By Reuters

Pfizer to cut 500 jobs at Kent site - Sky News…

Better Growth Stock: Pfizer vs. Novo Nordisk

One is growing now, and the other will grow soon.…

Top Analyst Reports for Meta Platforms, Walmart & Pfizer

Todays Research Daily features new research reports on 16 major stocks, including Meta Platforms, Inc. (META), Walmart Inc. (WMT) and…

Pfizer Stock Hits 3-Year Low—Down 50% From 2021 Peak

Excluding a brief early 2020 plunge, Pfizer shares are now trading at their lowest level since 2016.…

US Gastroenterologist Projections Suggest Significant Shift in Ulcerative Colitis Landscape Afoot, with Launches of Eli Lillys Omvoh, Pfizers Velsipity, Takedas Subcutaneous Entyvio, and Celltrions Zymfentra

Prior to launch, prescribers estimate that TNF inhibitors are likely to bear the greatest brunt of increased adoption of the…

Opening Bell: US-Investoren vor Inflationsdaten an der Seitenlinie; Pfizer, AMD, Palo Alto Networks, Dell, Waste Management im Fokus

Am Freitag noch im Rally-Modus, zum Wochenauftakt an der Seitenlinie: Die US-Investoren üben sich am Montag in Zurückhaltung. In der…

Pfizer wants in on the weight loss drug market – and upcoming data will be crucial for its success

Analysts said upcoming data on Pfizers obesity pill, danuglipron, will be crucial to how competitive the company can be against…

Eilt: Biotech Hot Stock unmittelbar vor globalem Lizenzdeal. Neuer 384% Biotech Aktientip nach 10.996% mit Pfizer ($PFE)

Calgary (www.aktiencheck.de, Anzeige) Einschätzung Strong OutperformerKurszieleKursziel 12M: 9 USD Kurschance: 223% Kursziel 24M: 13,50 USD Kurschance: 384%StammdatenISIN: CA98420Q3061 WKN: A3EUNZ Ticker: ANUA TSXV: XRTX.V NASDAQ: XRTXKursdatenKurs: 2,79 USD 52W Hoch:…

dpa-AFX ProFeed